Teva’s New Real-World Evidence Presented at ... - Teva Pharmaceuticals
Apr 16, 2024 · The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia. …
Teva’s New Real-World Evidence Confirms Effectiveness and Patient ...
Apr 19, 2024 · About AUSTEDO XR Extended-Release Tablets and AUSTEDO Tablets AUSTEDO XR and AUSTEDO are the first vesicular monoamine transporter 2 (VMAT2) inhibitors approved by the …
Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended ...
Sep 6, 2023 · Teva will share 16 data presentations across its neuroscience portfolio including AUSTEDO, once-daily AUSTEDO XR, UZEDY, TV-44749 (olanzapine) and AJOVY® …
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR ...
Nov 7, 2025 · The findings demonstrate that treatment with AUSTEDO (deutetrabenazine) tablets or AUSTEDO XR (deutetrabenazine) extended-release tablets for tardive dyskinesia (TD) led to …
Teva’s AUSTEDO and AUSTEDO XR demonstrate real-world …
Nov 11, 2025 · The results, presented at the 2025 Neuroscience Education Institute Fall Congress in Colorado Springs, Colorado, demonstrated that treatment with AUSTEDO or AUSTEDO XR led to …
Teva’s New Real-World Evidence Presented at the 2024 AAN
Apr 16, 2024 · The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia. …
Teva's AUSTEDO XR Shows 94% Movement Improvement in TD …
Sep 21, 2025 · Teva Pharmaceuticals (NYSE: TEVA) presented positive real-world survey data for AUSTEDO XR® (deutetrabenazine) at the 2025 Psych Congress Annual Meeting. The survey of 209 …
Teva’s New Real-World Evidence Presented at the 2024 AAN ... - Nasdaq
The START study was a Phase 4 study investigating real-world treatment outcomes for patients starting AUSTEDO with the 4-week Titration Kit.
Teva Pharmaceutical Industries Ltd. - Teva’s New Real-World Evidence ...
Apr 16, 2024 · Almost 80% of patients with Huntington's disease (HD) chorea were able to achieve optimal dosing within four weeks with the 4-week Titration Kit in final START study results START …
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release …
Sep 20, 2025 · The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia. …